R

Roche

Global pharmaceuticals and diagnostics company

Senior Group Director - Technical Regulatory Affairs

Full-TimeUpdated on 10/15/2026
No salary listed
Expert
Master's
Beijing, China+1 moreMore locations: Shanghai, China
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • At least 8 years of work experience in the pharmaceutical, biotechnology, or related industry, with experience in CMC, quality, regulatory, or a related area.
  • Proven knowledge of China Health Authority guidelines and experience interacting with health authorities.
  • Proven track record of developing regulatory strategies and scenario planning with robust regulatory risk assessment.
  • Technical understanding of drug substance and product manufacturing in small molecules and/or large molecules, and product development processes as appropriate.
  • Knowledge of drug development, commercialization processes, supply chain complexity, Pharmaceutical Quality Systems, and multidisciplinary functions involved in drug development, manufacturing, commercialization, and product lifecycle management.
  • Ability to build and maintain productive, trusted relationships across departments, with external partners and regulators, and across companies and cultures.
  • Ability to develop people through coaching.
  • Organizational and time-management skills, with ability to work under pressure.
  • Influencing and negotiation skills to achieve business results through collaboration across levels and organizations, identifying solutions that balance the needs of all parties.
  • Interpersonal and collaboration skills, with a track record of building strong, sustainable relationships with internal and external partners and stakeholders.
  • Ability to demonstrate Roche Values and Leadership Competencies.
  • Communication and presentation skills, with professional maturity, confidence, and competence.
  • Ability to synthesize and summarize complex issues and conclusions to expedite agreement and decision-making.
Responsibilities
  • Lead a team of China Technical Partners and CMC professionals accountable for China regulatory CMC submissions, developing and implementing end-to-end China filing strategies in collaboration with global development teams and based on China business priorities and regulatory requirements.
  • Lead and coach team members to accelerate drug access and continuous supply by ensuring right-first-time submissions to Chinese Health Authorities and effective Health Authority interactions.
  • Shape the regulatory environment in China in collaboration with PTR Policy and translate it into regulatory strategies.
  • Manage China Technical Partners and CMC program managers by setting performance objectives, providing timely feedback, and aligning short-term development goals with longer-term career goals.
  • Guide and manage others’ work activities for specific projects and objectives; adapt coaching to individual needs and provide coaching and mentoring.
  • Lead cross-functional regulatory initiatives and strategies, define critical steps and resources, and take responsibility for implementation.
  • Communicate proactively with regulatory and cross-functional personnel in support of internal and partner-associated project goals.
  • Collaborate with management to lead communications with Health Authorities on complex projects and initiatives, making decisions based on cross-functional rather than functional priorities.
  • Provide leadership to a team of regulatory professionals and manage employee performance.
  • Work with direct reports to provide objective, timely feedback and support employee development through regular development discussions and check-ins.
  • Provide coaching and mentoring to colleagues in an assigned area of technical regulatory responsibility.
  • Work closely with the Portfolio Leader to coordinate resources and priorities at portfolio level.
  • Follow up on project progress, guide the team in developing submission strategies for different applications, identify regulatory risks, and develop mitigation plans.
  • Build and maintain relationships with internal and external key stakeholders, including NMPA, CDE, NIFDC, Supply Chain, Quality and Compliance, PDR China, and PTR Global.
  • Collaborate with internal stakeholders to develop and align technical strategy, balancing regulatory and supply needs in China.
Desired Qualifications
  • A Master’s degree in a life science discipline is preferred; a postgraduate degree is a plus.
  • Previous people-management or cross-functional team-leadership experience is desired.
  • Track record of team leadership, preferably with cross-functional teams.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.

PR Newswire
Sep 30th, 2026
Roche launches newborn screening test for SMA, SCID and sickle cell disease

Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.

World Today News
Sep 8th, 2026
Tempus AI raises $600M to scale AI-enhanced liquid biopsy platform for cancer recurrence detection

Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.